戻る Agenda
Session 3 Track 3 - New Realities: Regulatory-Driven Research Networks: A New Frontier in Pharmacovigilance Worldwide
Session Chair(s)
Co Pham
Senior Scientific Advisor, Marketed Health Products Directorate
Health Canada, Canada
Finding solutions for public health problems and optimizing patient’s wellness is impacting the development of drugs as well as their post approval surveillance. From translational medicine bringing research scientists and industry together, to research networks responding to the need for real-world knowledge about drug safety and effectiveness, this session will explore how real world settings are impacting regulatory decision making and undertaking high quality post-market research.
Speaker(s)
Importance of Real-World Drug Safety & Effectiveness Research to Regulatory Decision-Making in Post-Market
Scott Sawler, LLM, MBA
Health Canada, Canada
Director General, Marketed Health Products Directorate
Importance of Real-World Drug Safety & Effectiveness Research to Regulatory Decision-Making in Post-Market
Robert G. Peterson, MD, PhD, MPH
Canadian Institutes of Health Research, Canada
Executive Director, Drug Safety and Effectiveness Network (DSEN)
Knowledge Translation / Translational Medicine
Sharon Straus, MD
University of Toronto, Canada
Professor, Department of Medicine